Related Experiment Video
Updated: Jun 23, 2026
08:03
Cervical Lymph Duct-Cannulated Rat Model for Assessing Lymphatic Transport from the Head and Brain
Published on: March 10, 2026
Therapeutic challenges in primary CNS lymphoma.
Patrick G Morris1, Lauren E Abrey
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
The Lancet. Neurology
|May 19, 2009
Summary
Treating primary CNS lymphoma is difficult due to its rarity and the blood-brain barrier. High-dose methotrexate and polychemotherapy are breakthroughs, with new targeted drugs showing promise for better outcomes.
Area of Science:
- Neuro-oncology
- Hematology
- Clinical Trials
Background:
- Primary CNS lymphoma (PCNSL) treatment is challenging due to rarity and lack of large trials.
- Systemic lymphoma drugs are often ineffective due to the blood-brain barrier (BBB).
Purpose of the Study:
- To review current treatment strategies for primary CNS lymphoma.
- To highlight therapeutic advances and future research directions.
Main Methods:
- Review of existing literature on PCNSL treatment.
- Analysis of drug efficacy and toxicity, particularly concerning the BBB.
- Discussion of chemotherapy, radiotherapy, and novel targeted therapies.
Main Results:
- High-dose methotrexate represents a significant therapeutic breakthrough.
- Polychemotherapy regimens and BBB disruption enhance treatment efficacy.
- Whole-brain radiotherapy can improve response but has significant toxicities.
Conclusions:
- Optimizing multi-drug chemotherapy and incorporating targeted agents are key to improving survival and reducing toxicity.
- Future advances in PCNSL treatment depend on enhanced research collaboration.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.